---
title: "Humira (adalimumab), all indications: Specific populations questions"
description: "Specific populations questions on Humira (adalimumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding. Questions: Can Humira be used during pregnancy? Can Humira be used while breastfeeding? Has Humira been studied in kidney or liver impairment? What happens after a Humira overdose? 4 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/humira/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Humira (adalimumab), all indications: Specific populations questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Humira](https://www.rxabbvie.com/pdf/humira.pdf)  
Indication pages: [Rheumatoid arthritis](https://www.evicenter.com/medical-information/humira--rheumatoid-arthritis)

## Pregnancy and breastfeeding

<a id="humira-pregnancy"></a>

### Can Humira be used during pregnancy?

> “Available studies with use of adalimumab during pregnancy do not reliably establish an 
> association between adalimumab and major birth defects. Clinical data are available from the 
> Organization of Teratology Information Specialists (OTIS)/MotherToBaby HUMIRA Pregnancy 
> Registry in pregnant women with rheumatoid arthritis (RA) or Crohn’s disease (CD). Registry 
> results showed a rate of 10% for major birth defects with first trimester use of adalimumab in 
> pregnant women with RA or CD and a rate of 7.5% for major birth defects in the disease-
> matched comparison cohort.”

Source: [HUMIRA: Prescribing information, page 23, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=23)

> “Adalimumab is actively transferred across the placenta during the third trimester of pregnancy 
> and may affect immune response in the in-utero exposed infant (see Clinical Considerations).”

Source: [HUMIRA: Prescribing information, page 24, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=24)

> “Published data suggest that the risk of adverse pregnancy outcomes in women with RA or 
> inflammatory bowel disease (IBD) is associated with increased disease activity. Adverse 
> pregnancy outcomes include preterm delivery (before 37 weeks of gestation), low birth weight 
> (less than 2500 g) infants, and small for gestational age at birth.”

Source: [HUMIRA: Prescribing information, page 24, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=24)

> “Risks and benefits 
> should be considered prior to administering live or live-attenuated vaccines to infants exposed to 
> HUMIRA in utero [see Use in Specific Populations (8.4)].”

Source: [HUMIRA: Prescribing information, page 24, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=24)

<a id="humira-breastfeeding"></a>

### Can Humira be used while breastfeeding?

> “Limited data from case reports in the published literature describe the presence of adalimumab in 
> human milk at infant doses of 0.1% to 1% of the maternal serum concentration. Published data 
> suggest that the systemic exposure to a breastfed infant is expected to be low because 
> adalimumab is a large molecule and is degraded in the gastrointestinal tract. However, the effects 
> of local exposure in the gastrointestinal tract are unknown. There are no reports of adverse 
> effects of adalimumab on the breastfed infant and no effects on milk production. The 
> developmental and health benefits of breastfeeding should be considered along with the mother’s 
> clinical need for HUMIRA and any potential adverse effects on the breastfed child from 
> HUMIRA or from the underlying maternal condition.”

Source: [HUMIRA: Prescribing information, page 25, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=25)

## Specific populations

<a id="humira-kidney-liver-impairment"></a>

### Has Humira been studied in kidney or liver impairment?

> “Patients with Renal or Hepatic Impairment: No pharmacokinetic data are available in patients 
> with hepatic or renal impairment.”

Source: [HUMIRA: Prescribing information, page 31, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=31)

<a id="humira-overdose"></a>

### What happens after a Humira overdose?

> “Doses up to 10 mg/kg have been administered to patients in clinical trials without evidence of 
> dose-limiting toxicities. In case of overdosage, it is recommended that the patient be monitored 
> for any signs or symptoms of adverse reactions or effects and appropriate symptomatic treatment 
> instituted immediately.  
>
> Consider contacting the Poison Help line (1-800-222-1222) or medical toxicologist for additional 
> overdose management recommendations.”

Source: [HUMIRA: Prescribing information, page 27, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=27)

## Related pages
- [Medical information: Humira (adalimumab): All indications](https://www.evicenter.com/medical-information/humira)
- [Indication](https://www.evicenter.com/medical-information/humira/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/humira/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/humira/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/humira/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/humira/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/humira/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/humira/access-and-coverage)
